Syntara Limited has released a press release.
Skin scarring program to progress on positive Phase1a result
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Quarterly Shareholder Report and Appendix 4C
- Positive top-line Phase 2a data confirms competitive profile
- Preliminary Final Report
- Guidance from FDA on amsulostat clinical progression
- Reinstatement to Quotation
Later from Syntara
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Amsulostat and Garvan in MRFF funded pancreatic trial
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report and Appendix 4D
- Positive FDA feedback for Amsulostat P2b trial
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara